Compare Amylx Pharmaceuticals Inc (AMLX) vs CarMax, Inc (KMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs CarMax, Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while CarMax, Inc trades at $53.68 (market cap $7.59B). The key difference: CarMax, Inc is far larger — about 3.8× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | KMX | |
|---|---|---|
Market Cap | $1.98B | $7.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $65.20 |
52-Week Low | $7.64 | $30.88 |
Enterprise Value | $1.70B | $26.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
CarMax (KMX) trades at $53.49, up 4.86% with a bullish technical signal. The stock shows mixed fundamentals with a P/E of 33.22 and net margin of 0.84%, though recent Q1 2026 earnings beat expectations. Revenue trends downward from $31.9B in 2022 to $26.4B in 2025, while net cash flow turned negative at -$290M. Analyst sentiment is cautious with 62.9% hold ratings and a $48.91 consensus target below current price. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr.
KMX presents a speculative opportunity amid transition, with potential upside from execution of digital and cost initiatives. Key risks include margin pressure, high debt load ($18.1B long-term), and investigation concerns. Near-term resistance at $53, support at $49. Wall Street remains neutral pending clearer turnaround evidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
